BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Deals

  Fresenius SE & Co. KGaA to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 13 November 2019

  Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

  November 6, 2019

   · 

  2 min read
• Business

  Protagonist Therapeutics Reports Third Quarter 2019 Financial Results

  Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019

  November 6, 2019

   · 

  10 min read
• Deals

  CRH Medical Receives TSX Approval for Renewal of Normal Course Issuer Bid - Nov. 6, 2019

  CRH Medical Corporation, announces that it has received approval from the Toronto Stock Exchange of its Notice of Intention to renew its existing Normal Course Issuer Bid.

  November 6, 2019

   · 

  12 min read
• Drug Development

  The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019

  The Medicines Company announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science sessions at the American Heart Association Scientific Sessions 2019, November 16-18, in Philadelphia.

  November 6, 2019

   · 

  7 min read
• Business

  New White Paper To Detail European Biosimilar Evolution and Policy Principles

  The Alliance for Safe Biologic Medicines released an abstract from a forthcoming white paper that provides a comprehensive overview of the evolution of the European biosimilars market.

  November 6, 2019

   · 

  1 min read
• Business

  Biostage to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Business Update

  Biostage, Inc., a bioengineering company developing next-generation esophageal implants, announced that it will report its financial results for the three and nine months ended September 30, 2019 in a press release that will be issued pre-market on Tuesday November 12, 2019.

  November 6, 2019

   · 

  1 min read
• Business

  Tocagen to Report Third Quarter 2019 Financial Results and Business Updates on Tuesday, November 12

  Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, announced it will report its third quarter 2019 financial results and business progress on Tuesday, November 12, 2019, after the close of the U.S. financial markets.

  November 6, 2019

   · 

  1 min read
• Business

  Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

  Evofem Biosciences, Inc. a clinical-stage biopharmaceutical company, reported financial results for the three- and nine-month periods ended September 30, 2019.

  November 6, 2019

   · 

  9 min read
• Business

  PDL BioPharma Reports 2019 Third Quarter Financial Results

  Revenues of $44.2 million includes continued growth from LENSAR and strong contribution from royalty assets

  November 6, 2019

   · 

  17 min read
• Business

  Invitae Reports $56.5 Million in 2019 Quarterly Revenue Driven by 129,000 Samples

  Invitae Corporation, a leading medical genetics company, announced financial and operating results for the third quarter ended September 30, 2019.

  November 6, 2019

   · 

  16 min read